Your browser is no longer supported. Please, upgrade your browser.
Catalent, Inc.
IndexS&P 500 P/E39.29 EPS (ttm)2.96 Insider Own0.20% Shs Outstand170.50M Perf Week6.49%
Market Cap19.62B Forward P/E34.74 EPS next Y3.35 Insider Trans-43.72% Shs Float169.41M Perf Month6.57%
Income496.80M PEG2.31 EPS next Q1.03 Inst Own99.83% Short Float1.09% Perf Quarter1.19%
Sales3.76B P/S5.22 EPS this Y20.60% Inst Trans2.31% Short Ratio2.02 Perf Half Y-0.48%
Book/sh21.78 P/B5.34 EPS next Y16.26% ROA6.10% Target Price134.70 Perf Year39.27%
Cash/sh6.30 P/C18.46 EPS next 5Y17.00% ROE15.10% 52W Range79.65 - 127.68 Perf YTD11.71%
Dividend- P/FCF- EPS past 5Y-8.30% ROI5.70% 52W High-8.94% Beta1.42
Dividend %- Quick Ratio1.90 Sales past 5Y11.10% Gross Margin33.20% 52W Low45.96% ATR2.01
Employees13900 Current Ratio2.40 Sales Q/Q38.50% Oper. Margin19.40% RSI (14)66.44 Volatility1.87% 1.71%
OptionableYes Debt/Eq0.87 EPS Q/Q1009.10% Profit Margin13.20% Rel Volume0.61 Prev Close115.19
ShortableYes LT Debt/Eq0.85 EarningsMay 04 BMO Payout0.00% Avg Volume915.14K Price116.26
Recom1.70 SMA204.26% SMA508.15% SMA2009.77% Volume558,510 Change0.93%
Dec-10-20Upgrade KeyBanc Capital Markets Sector Weight → Overweight $120
Jun-25-20Initiated Argus Buy $100
Apr-21-20Initiated RBC Capital Mkts Outperform $65
Mar-02-20Initiated Deutsche Bank Hold
Oct-17-19Resumed Stephens Overweight $56
Aug-28-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jun-21-19Upgrade Jefferies Hold → Buy $50 → $62
Apr-16-19Upgrade UBS Neutral → Buy $43 → $54
Nov-07-18Upgrade First Analysis Sec Neutral → Outperform $47 → $43
Oct-09-18Initiated UBS Neutral
Mar-28-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Mar-21-18Upgrade Raymond James Mkt Perform → Outperform
Feb-06-18Downgrade Stephens Overweight → Equal-Weight
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-13-17Initiated Needham Hold
Sep-08-17Downgrade KeyBanc Capital Mkts Overweight → Sector Weight
Dec-01-16Initiated Goldman Neutral
Oct-20-16Initiated KeyBanc Capital Mkts Overweight $29
Jun-21-16Upgrade Wells Fargo Market Perform → Outperform
Jun-20-16Upgrade BofA/Merrill Neutral → Buy
Jul-22-21 11:32AM  
Jul-21-21 02:14PM  
Jul-15-21 10:43AM  
Jul-14-21 09:52AM  
Jul-07-21 09:00AM  
Jul-06-21 11:28AM  
Jul-02-21 07:56AM  
Jun-29-21 11:34AM  
Jun-28-21 11:24AM  
Jun-25-21 10:02AM  
Jun-09-21 11:00AM  
Jun-04-21 09:00AM  
Jun-03-21 08:33AM  
May-28-21 08:48AM  
May-21-21 08:45AM  
May-13-21 08:59AM  
May-11-21 07:00AM  
May-10-21 04:44PM  
May-07-21 09:00AM  
May-06-21 03:13PM  
May-04-21 03:00PM  
Apr-23-21 02:22AM  
Apr-21-21 05:39PM  
Apr-19-21 08:30AM  
Apr-13-21 08:59AM  
Apr-12-21 04:49PM  
Apr-07-21 08:00AM  
Apr-06-21 09:00AM  
Mar-31-21 06:52PM  
Mar-29-21 01:58PM  
Mar-25-21 09:50AM  
Mar-24-21 02:13AM  
Mar-23-21 02:32PM  
Mar-22-21 07:15AM  
Mar-18-21 02:58AM  
Mar-17-21 08:00PM  
Mar-16-21 08:00PM  
Mar-15-21 06:01AM  
Mar-02-21 01:30PM  
Mar-01-21 02:52PM  
Feb-25-21 12:46PM  
Feb-24-21 04:10PM  
Feb-19-21 04:15PM  
Feb-18-21 01:15PM  
Feb-16-21 04:02PM  
Feb-11-21 11:40AM  
Feb-10-21 04:49PM  
Feb-09-21 12:45PM  
Feb-03-21 04:30PM  
Feb-02-21 02:30PM  
Feb-01-21 10:38AM  
Jan-26-21 12:31PM  
Jan-20-21 08:45AM  
Jan-18-21 12:10PM  
Jan-16-21 08:00AM  
Jan-14-21 12:34PM  
Jan-13-21 07:25AM  
Jan-11-21 12:41AM  
Jan-06-21 08:55AM  
Jan-05-21 12:45PM  
Dec-28-20 08:32AM  
Dec-24-20 12:00PM  
Dec-15-20 11:45AM  
Dec-11-20 10:54AM  
Dec-10-20 09:30PM  
Dec-06-20 02:22AM  
Nov-27-20 08:30AM  
Nov-19-20 10:08AM  
Nov-18-20 04:23PM  
Nov-16-20 10:06AM  
Nov-13-20 09:42AM  
Nov-11-20 09:16AM  
Nov-09-20 02:47PM  
Nov-06-20 06:03AM  
Nov-03-20 02:31PM  
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fasman Steven LSVP & General CounselJul 15Sale109.864,500494,35368,912Jul 16 01:06 PM
Pravda RicardoSVP & Chief HR OfficerJun 23Sale110.582,800309,62411,070Jun 24 06:10 PM
Schmidt Kay ASVP, Technical OperationsMar 22Sale105.771,400148,07813,866Mar 23 07:27 PM
Chiminski John RChair & CEOMar 19Option Exercise42.06183,0247,698,674346,642Mar 22 02:19 PM
Chiminski John RChair & CEOMar 19Sale106.01183,02419,402,784163,618Mar 22 02:19 PM
Fasman Steven LSVP & General CounselMar 18Option Exercise38.7821,647839,44594,954Mar 22 02:20 PM
Chiminski John RChair & CEOMar 18Option Exercise36.0242,2201,520,764205,838Mar 22 02:19 PM
Chiminski John RChair & CEOMar 18Sale105.1642,2204,439,855163,618Mar 22 02:19 PM
Fasman Steven LSVP & General CounselMar 18Sale104.5321,6472,262,77073,307Mar 22 02:20 PM
Joseph WettenySVP & Chief Financial OfficerFeb 16Option Exercise52.565,000262,79954,823Feb 18 09:56 AM
Joseph WettenySVP & Chief Financial OfficerFeb 16Sale124.545,000622,68549,823Feb 18 09:56 AM
Joseph WettenySVP & Chief Financial OfficerFeb 08Sale113.734,604523,61349,823Feb 10 09:05 AM
Whitlow Ricci SPresident, CSSJan 21Sale118.8569282,2442,576Jan 25 07:17 AM
Flynn KarenPres. Biologics & CCOJan 11Sale112.302,478278,27934,544Jan 11 07:12 PM
Gunther ScottSVP, Quality & Reg. AffairsJan 06Sale104.78616,39216,509Jan 07 07:04 AM
Schmidt Kay ASVP, Technical OperationsJan 04Sale104.42737,62315,266Jan 05 09:47 PM
Whitlow Ricci SPresident, CSSJan 04Sale104.42838,6673,268Jan 05 09:47 PM
Joseph WettenySVP & Chief Financial OfficerJan 04Sale104.4217217,96054,427Jan 05 09:46 PM
Maselli AlessandroPresident & COOJan 04Sale104.4214815,45419,618Jan 05 09:46 PM
Pravda RicardoSVP & Chief HR OfficerJan 04Sale104.42788,14513,870Jan 05 09:46 PM
Gennadios AristipposPresident Softgel & Oral TechJan 04Sale104.4211011,48651,315Jan 05 09:45 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Jan 04Sale104.4212613,15717,076Jan 05 09:45 PM
Gunther ScottSVP, Quality & Reg. AffairsJan 04Sale104.4212012,53016,570Jan 05 09:45 PM
Arnold JonathanPres. Oral & Specialty Deliv.Jan 04Sale104.42161,67138,602Jan 05 09:44 PM
Fasman Steven LSVP & General CounselJan 04Sale104.4218919,73573,307Jan 05 09:44 PM
Flynn KarenPres. Biologics & CCOJan 04Sale104.429910,33837,022Jan 05 09:44 PM
Gennadios AristipposPresident Softgel & Oral TechDec 21Option Exercise32.6813,662446,52661,151Dec 23 07:19 AM
Gennadios AristipposPresident Softgel & Oral TechDec 21Sale102.8413,6621,405,04451,425Dec 23 07:19 AM
Zippelius PeterDirectorNov 23Sale99.265,392,280535,237,7130Nov 25 05:53 PM
Fasman Steven LSVP & General CounselNov 11Sale100.992,425244,90173,496Nov 12 12:21 PM
Fasman Steven LSVP & General CounselOct 14Option Exercise26.1815,025393,42687,460Oct 16 06:13 PM
Fasman Steven LSVP & General CounselOct 14Sale93.095,510512,93475,921Oct 16 06:13 PM
Schmidt Kay ASVP, Technical OperationsOct 14Sale93.152,985278,04515,764Oct 16 06:13 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Oct 12Sale94.991,680159,58317,202Oct 13 08:24 AM
Arnold JonathanPres. Oral & Specialty Deliv.Oct 07Option Exercise30.8439,3421,213,36477,960Oct 09 03:24 PM
Arnold JonathanPres. Oral & Specialty Deliv.Oct 07Sale91.5015,9281,457,41238,618Oct 09 03:24 PM
Gunther ScottSVP, Quality & Reg. AffairsOct 02Option Exercise36.027,347264,63926,249Oct 05 07:55 PM
Chiminski John RChair & CEOOct 02Option Exercise29.90138,1354,130,817404,337Oct 05 07:55 PM
Chiminski John RChair & CEOOct 02Sale86.01182,23115,673,809173,618Oct 05 07:55 PM
Gunther ScottSVP, Quality & Reg. AffairsOct 02Sale85.484,359372,60816,690Oct 05 07:55 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Sep 02Sale89.502,250201,37818,882Sep 08 01:21 PM
LUCIER GREGORY TDirectorJul 30Sale90.0924,0002,162,16016,921Aug 03 12:02 PM